BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24343972)

  • 1. CIITA: a master regulator of adaptive immunity shows its innate side in the bone.
    Nakamura MC
    J Bone Miner Res; 2014 Feb; 29(2):287-9. PubMed ID: 24343972
    [No Abstract]   [Full Text] [Related]  

  • 2. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
    Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
    J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.
    LeibundGut-Landmann S; Waldburger JM; Krawczyk M; Otten LA; Suter T; Fontana A; Acha-Orbea H; Reith W
    Eur J Immunol; 2004 Jun; 34(6):1513-25. PubMed ID: 15162420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage-specific MHCII expression is regulated by a remote
    Buxadé M; Huerga Encabo H; Riera-Borrull M; Quintana-Gallardo L; López-Cotarelo P; Tellechea M; Martínez-Martínez S; Redondo JM; Martín-Caballero J; Flores JM; Bosch E; Rodríguez-Fernández JL; Aramburu J; López-Rodríguez C
    J Exp Med; 2018 Nov; 215(11):2901-2918. PubMed ID: 30327417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.
    Smith MA; Wright G; Wu J; Tailor P; Ozato K; Chen X; Wei S; Piskurich JF; Ting JP; Wright KL
    J Biol Chem; 2011 Mar; 286(10):7893-7904. PubMed ID: 21216962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1.
    Forlani G; Shallak M; Ramia E; Tedeschi A; Accolla RS
    Retrovirology; 2019 Nov; 16(1):34. PubMed ID: 31783769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells.
    Sebastián C; Serra M; Yeramian A; Serrat N; Lloberas J; Celada A
    J Immunol; 2008 May; 180(9):5898-906. PubMed ID: 18424709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator.
    Voong LN; Slater AR; Kratovac S; Cressman DE
    J Biol Chem; 2008 Apr; 283(14):9031-9. PubMed ID: 18245089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NLRC5: a key regulator of MHC class I-dependent immune responses.
    Kobayashi KS; van den Elsen PJ
    Nat Rev Immunol; 2012 Dec; 12(12):813-20. PubMed ID: 23175229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.
    Kim D; Hoory T; Monie A; Ting JP; Hung CF; Wu TC
    J Immunol; 2008 May; 180(10):7019-27. PubMed ID: 18453624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells.
    Yoon HS; Scharer CD; Majumder P; Davis CW; Butler R; Zinzow-Kramer W; Skountzou I; Koutsonanos DG; Ahmed R; Boss JM
    J Immunol; 2012 Sep; 189(5):2393-403. PubMed ID: 22851713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
    Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
    J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymus.
    Patel DR; Li W; Park JS; Sofi MH; Gourley TS; Hangoc G; Kaplan MH; Chang CH
    Cell Immunol; 2005 Jan; 233(1):30-40. PubMed ID: 15876426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes.
    Otten LA; Tacchini-Cottier F; Lohoff M; Annunziato F; Cosmi L; Scarpellino L; Louis J; Steimle V; Reith W; Acha-Orbea H
    J Immunol; 2003 Feb; 170(3):1150-7. PubMed ID: 12538670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
    Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
    J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
    Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
    Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIITA promoter I CARD-deficient mice express functional MHC class II genes in myeloid and lymphoid compartments.
    Zinzow-Kramer WM; Long AB; Youngblood BA; Rosenthal KM; Butler R; Mohammed AU; Skountzou I; Ahmed R; Evavold BD; Boss JM
    Genes Immun; 2012 Jun; 13(4):299-310. PubMed ID: 22218223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA.
    Pan H; O'Brien TF; Wright G; Yang J; Shin J; Wright KL; Zhong XP
    J Immunol; 2013 Jul; 191(2):699-707. PubMed ID: 23776173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC class II transactivator represses human IL-4 gene transcription by interruption of promoter binding with CBP/p300, STAT6 and NFAT1 via histone hypoacetylation.
    Zhou X; Jiang Y; Lu L; Ding Q; Jiao Z; Zhou Y; Xin L; Chou KY
    Immunology; 2007 Dec; 122(4):476-85. PubMed ID: 17645498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Function and regulation of class II transactivator in the immune system.
    Chang CH; Gourley TS; Sisk TJ
    Immunol Res; 2002; 25(2):131-42. PubMed ID: 11999167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.